secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: June 9, 1997.

#### LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 97–15546 Filed 6–12–97; 8:45 am] BILLING CODE 4140–01–M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

## National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of General Medical Sciences meeting:

Committee Name: Minority Biomedical Research Support, Review Subcommittee—Panel2.

Date: June 13, 1997.

Time of Meeting: 8:30 a.m.—adjournment. Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, N.W., Washington, D.C. 20007.

Contact Person: Arthur L. Zachary, Ph.D. Scientific Review Administrator, NIGMS 45 Center Drive, Room 1AS–13 Bethesda, MD 20892–6200 301–594–2886.

*Purpose:* To review Institutional research training grant applications.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS]) Dated: June 10, 1997.

#### LaVerne Y. Stringfield,

Committee Management Officer, NIH.
[FR Doc. 97–15547 Filed 6–12–97; 8:45 am]
BILLING CODE 4140–01–M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

# Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

Name of SEP: Chemistry and Related Sciences.

Date: July 9, 1997.

Time: 1:00 p.m.

*Place:* NIH, Rockledge 2, Room 5106; Telephone Conference.

Contact Person: Dr. Richard Panniers, Scientific Review Administrator, 6701 Rockledge Drive, Room 5106, Bethesda, Maryland 20892; (301) 435–1166.

*Name of SEP:* Chemistry and Related Sciences.

Date: July 22, 1997.

Time: 10:00 a.m.

*Place:* NIH, Rockledge 2, Room 4156; Telephone Conference.

Contact Person: Dr. Ronald Dubois, Scientific Review Administrator, 6701 Rockledge Drive, Room 4156, Bethesda, Maryland 20892; (301) 435–1722.

 $\it Name\ of\ SEP:$  Biological and Physiological Sciences.

Date: August 7, 1997.

Time: 1:00 p.m.

Place: Holiday Inn-Georgetown,

Washington, DC.

Contact Person: Dr. Krish Krishnan, Scientific Review Administrator, 6701 Rockledge Drive, Room 4122, Bethesda, Maryland 20892; (301) 435–1779.

*Purpose/Agenda:* To review Small Business Innovation Research.

Name of SEP: Multidisciplinary Sciences.

Date: July 14, 1997.

Time: 8:30 a.m.

Place: Holiday Inn-Georgetown,

Washington, DC.

Contact Person: Dr. Lee Rosen, Scientific Review Administrator, 6701 Rockledge Drive, Room 5116, Bethesda, Maryland 20892; (301) 435–1171.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure

of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846—93.878, 93.892, 93,893, National Institutes of Health, HHS)

Dated: June 9, 1997.

### LaVerne Y. Stringfield,

Committee Management Officer, NIH.
[FR Doc. 97–15545 Filed 6–12–97; 8:45 am]
BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Substance Abuse and Mental Health Services Administration**

# Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Drug Testing Advisory Board (DTAB) of the Center for Substance Abuse Prevention in August 1997.

The two-day scientific meeting will be to continue discussing alternative specimens and technologies of drug testing (i.e., hair, saliva, sweat, and noninstrument based on-site tests) as they apply to workplace drug testing programs. The entire meeting is open to the public; however, attendance by the public will be limited to space available. Therefore, it would be helpful if those planning to attend would pre-register by following Registration instructions below. There will be a very limited time for public comment during the meeting. Any individual desiring to make a formal comment should notify the contact person listed below before July

The purpose of the meeting is: (1) To review the proposed principles and criteria associated with a forensic workplace drug testing program presented at the April 28-30, 1997, DTAB meeting and determine if those are the appropriate standards that any drug testing program needs to satisfy; (2) to review the information and scientific studies presented or submitted by the representatives of the alternative specimens and technology industries during and/or after the April 28–30 DTAB meeting, to determine their strengths and weaknesses, what criteria they satisfy, and what areas may need improvement; and (3) to make recommendations to assist these alternative specimens and technologies to satisfy the criteria.

An agenda for this meeting and a roster of board members may be obtained from: Ms. Giselle Hersh, Division of Workplace Programs, Room